Cell-associated HIV-1 messenger RNA and DNA in T-helper cell and monocytes in asymptomatic HIV-1-infected subjects on HAART plus an inactivated HIV-1 immunogen.

Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Cell-associated HIV-1 messenger RNA and DNA in T-helper cell and monocytes in asymptomatic HIV-1-infected subjects on HAART plus an inactivated HIV-1 immunogen.

AIDS. 1999 Sep 10;13(13):1607-11. Unique Identifier : AIDSLINE MED/99437259
Patterson BK; Carlo DJ; Kaplan MH; Marecki M; Pawha S; Moss RB; Northwestern University Medical School, Department of; Obstetrics/Gynecology and Medicine, Chicago, Illinois 60611, USA.; bpatters@nmh.org

Abstract: OBJECTIVE: We examined the effect of an HIV-1-specific immune-based therapy on cell-associated HIV-1 DNA and RNA. DESIGN: Five HIV-1-infected subjects receiving HIV-1 immunogen plus HAART were compared with three HIV-1-infected subjects who received incomplete Freund's adjuvant (IFA) plus HAART. METHODS: Cell-associated HIV-1 RNA or DNA in lymphocytes and monocytes was determined using a dual immunophenotyping/in situ hybridization assay with or without in situ PCR amplification. RESULTS: Cell-associated HIV-1 RNA in CD4 cells correlated with plasma RNA overall. CD4, HIV-1 gag-pol messenger (m)RNA+ cells decreased in the immunogen plus HAART group compared with the IFA plus HAART group. Decreases in HIV-1 DNA+ CD4 cells were observed in the immunogen plus HAART compared with the IFA plus HAART group. Decreases in HIV-1 gag-pol mRNA+ monocytes were observed in the immunogen plus HAART group compared with the IFA plus HAART group. Consistent with the findings in CD4 cells, decreases in HIV-1 DNA+ monocytes were observed in the immunogen plus HAART group compared with the IFA plus HAART group. CONCLUSIONS: These preliminary observations support the rationale for examining the combination of immune-based therapies and antiretroviral drugs for effective HIV-1 control.

Keywords: CLINICAL TRIAL JOURNAL ARTICLE Anti-HIV Agents/*THERAPEUTIC USE AIDS Vaccines/*ADMINISTRATION & DOSAGE Combined Modality Therapy CD4 Lymphocyte Count Drug Therapy, Combination DNA, Viral/*ANALYSIS Freund's Adjuvant/ADMINISTRATION & DOSAGE Human HIV Infections/IMMUNOLOGY/*THERAPY/VIROLOGY HIV-1/GENETICS/IMMUNOLOGY/*ISOLATION & PURIF Indinavir/ADMINISTRATION & DOSAGE Lamivudine/ADMINISTRATION & DOSAGE Monocytes/*VIROLOGY Pilot Projects RNA, Viral/*ANALYSIS T-Lymphocytes, Helper-Inducer/*VIROLOGY Viral Load Zidovudine/ADMINISTRATION & DOSAGE

000130
A0011263

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .